According to Zhitong Finance App, Hanson Pharmaceuticals (03692) announced that on September 14, 2026, based on the positive results of the HS-20093 (injectable Ruikang rivolutamab) (this product) (this product) key phase III trial, the indications for the treatment of osteosarcoma patients aged ≥12 years who have failed at least second-line treatment were included in the China National Drug Administration (NMPA) priority review and approval process.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.